| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Review Of Trials Confirms Toxicity Of Lariam LONDON, ENGLAND -- November 28, 1997 -- In this week's British Medical Journal, Major Ashley Croft, consultant in public health medicine, Headquarters Defence Secondary Care Agency at the Ministry of Defence in London, England and his colleague confirm the theoretical efficacy of mefloquine in preventing malaria infection (first available to European travelers in 1985, as Lariam). The study reviewed 10 trials comprising a total of 2,750 non-immune adult participants randomised to mefloquine or to a control. One placebo controlled trial examined malaria incidence directly and showed mefloquine to be highly effective in preventing malaria in an area of drug resistance. However, four placebo controlled trials showed that mefloquine was not well tolerated and withdrawals were consistently higher in mefloquine treatment arms than in placebo arms. Five field trials compared mefloquine with other chemoprophylaxis. Mefloquine was no worse tolerated than other chemoprophylaxis, although there was possibly a trend towards higher withdrawals in mefloquine arms. The authors' study also reveals levels of high toxicity and that study participants were more likely to withdraw from taking mefloquine than from taking placebo, which could be due to side effects of the prophylaxis, such as insomnia and fatigue. The researchers concluded that their review suggests that the effectiveness of mefloquine is limited by low
|